BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 19878638)

  • 1. Novel therapies in the treatment of multiple myeloma.
    Laubach JP; Mitsiades CS; Mahindra A; Schlossman RL; Hideshima T; Chauhan D; Carreau NA; Ghobrial IM; Raje N; Munshi NC; Anderson KC; Richardson PG
    J Natl Compr Canc Netw; 2009 Oct; 7(9):947-60. PubMed ID: 19878638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Part I: the role of maintenance therapy in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation.
    McCarthy PL
    J Natl Compr Canc Netw; 2013 Jan; 11(1):35-42. PubMed ID: 23307979
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnosis and the current trends in multiple myeloma therapy.
    DmoszyƄska A
    Pol Arch Med Wewn; 2008 Oct; 118(10):563-6. PubMed ID: 19112817
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical update: novel targets in multiple myeloma.
    Anderson KC
    Semin Oncol; 2004 Dec; 31(6 Suppl 16):27-32; discussion 33. PubMed ID: 15799242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The emerging role of novel therapies for the treatment of relapsed myeloma.
    Richardson PG; Hideshima T; Mitsiades C; Anderson KC
    J Natl Compr Canc Netw; 2007 Feb; 5(2):149-62. PubMed ID: 17335684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma.
    Laubach JP; Schlossman RL; Mitsiades CS; Anderson KC; Richardson PG
    Expert Rev Hematol; 2011 Feb; 4(1):51-60. PubMed ID: 21322778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintenance treatment in multiple myeloma.
    Harousseau JL
    Ann Oncol; 2008 Jun; 19 Suppl 4():iv54-5. PubMed ID: 18519405
    [No Abstract]   [Full Text] [Related]  

  • 8. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
    Kumar S; Giralt S; Stadtmauer EA; Harousseau JL; Palumbo A; Bensinger W; Comenzo RL; Lentzsch S; Munshi N; Niesvizky R; San Miguel J; Ludwig H; Bergsagel L; Blade J; Lonial S; Anderson KC; Tosi P; Sonneveld P; Sezer O; Vesole D; Cavo M; Einsele H; Richardson PG; Durie BG; Rajkumar SV;
    Blood; 2009 Aug; 114(9):1729-35. PubMed ID: 19561323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of novel agents in the treatment of relapsed and refractory multiple myeloma.
    Laubach JP; Mahindra A; Mitsiades CS; Schlossman RL; Munshi NC; Ghobrial IM; Carreau N; Hideshima T; Anderson KC; Richardson PG
    Leukemia; 2009 Dec; 23(12):2222-32. PubMed ID: 19741729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multiple myeloma: novel approaches for relapsed disease.
    Lonial S
    Clin Lymphoma Myeloma; 2007 Dec; 8 Suppl 1():S18-23. PubMed ID: 18282362
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New therapies in multiple myeloma.
    Merchionne F; Perosa F; Dammacco F
    Clin Exp Med; 2007 Sep; 7(3):83-97. PubMed ID: 17972050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drugs for myeloma.
    Richardson PG; Mitsiades C; Schlossman R; Munshi N; Anderson K
    Oncologist; 2007 Jun; 12(6):664-89. PubMed ID: 17602058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.
    Yaqub S; Ballester G; Ballester O
    Cancer Invest; 2013 Oct; 31(8):529-37. PubMed ID: 24083815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel agents in the frontline management of multiple myeloma.
    Loong HH
    Hematol Oncol Stem Cell Ther; 2008; 1(4):201-9. PubMed ID: 20058474
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel agents for multiple myeloma treatment.
    Ribatti D; Vacca A
    Curr Pharm Biotechnol; 2006 Dec; 7(6):395. PubMed ID: 17168654
    [No Abstract]   [Full Text] [Related]  

  • 16. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials.
    Wang A; Duan Q; Liu X; Ding K; Han Y; Zhu W; Cai X; Wu J; Sun Z
    Ann Hematol; 2012 Nov; 91(11):1779-84. PubMed ID: 22773209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New treatments in multiple myeloma: beyond optimal treatment.
    Harousseau JL
    Ann Oncol; 2008 Jul; 19 Suppl 5():v68-70. PubMed ID: 18611904
    [No Abstract]   [Full Text] [Related]  

  • 18. Multiple myeloma.
    Raab MS; Podar K; Breitkreutz I; Richardson PG; Anderson KC
    Lancet; 2009 Jul; 374(9686):324-39. PubMed ID: 19541364
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extramedullary progression of multiple myeloma despite concomitant medullary response to multiple combination therapies and autologous transplant: a case report.
    Kumar AK; Dakhil C; Teeka Satyan M; Haideri N
    J Med Case Rep; 2014 Sep; 8():299. PubMed ID: 25200389
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status of new drugs for the treatment of patients with multiple myeloma.
    Kenealy M; Prince HM
    Intern Med J; 2006 Dec; 36(12):781-9. PubMed ID: 17096741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.